New vaccine development

BMJ

Volumn 324, Issue 7349, 2002, Pages 1315-

  Poland, Gregory A ^a   Murray, Dennis ^b   Bonilla Guerrero, Ruben ^a  

^a MAYO CLINIC   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; VACCINE; VIRUS VACCINE; COCAINE; NICOTINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE;

ADOLESCENT; AUTOIMMUNE DISEASE; BIOLOGICAL WARFARE; CHILD; HUMAN; IMMUNOLOGY; INFANT; PLANT; PRESCHOOL CHILD; RESEARCH; REVIEW; ALZHEIMER DISEASE; CANCER; COCAINE DEPENDENCE; CONTROLLED DRUG RELEASE; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFICACY; IMMUNIZATION; MEDLINE; PRIORITY JOURNAL; SMOKING CESSATION; TRANSGENIC PLANT; VACCINATION;

ADOLESCENT; AUTOIMMUNE DISEASES; BIOLOGICAL WARFARE; CANCER VACCINES; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; PLANTS, EDIBLE; RESEARCH; VACCINES; VACCINES, DNA; VIRAL VACCINES;

EID: 0036607367     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.324.7349.1315     Document Type: Article

References (38)

1. Centers for Disease Control. Ten great public health achievements–United States, 1900–1999. MMWR Morb Mortal Wkly Rep 1999; 48(12): 241–243.
2. Poland GA. Current paradoxes and changing paradigms in vaccinology. Vaccine 1999; 17: 1605–1611.
3. Dhiman N, Bonilla R, O'Kane D, Poland GA. Gene expression microarrays: a 21st century tool for directed vaccine design. Vaccine 2001; 20: 22–30.
4. Poland GA, Ovsyannikova IG, Johnson KL, Naylor S. The role of mass spectrometry in vaccine development. Vaccine 2001; 19: 2692–2700.
5. Plotkin SA. Vaccines in the 21st century. Infect Dis Clin North Am 2001; 15: 307–327.
6. Poland GA, Rottinghaus ST, Jacobson RM, Roy M. A phase 1C study of a DNA hepatitis B vaccine in healthy patients nonresponsive to licensed hepatitis B vaccines: preliminary results [abstract]. The fourth annual conference on vaccine research, Arlington, VA, April 23–25 2001;S37:57 (www.nfid.org/conferences/vaccine01/abstracts/abss37–40.pdf).
7. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282: 476–480.
8. Oka Y, Fazle Akbar SM, Horiike N, Joko K, Onji M. Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice. Immunology 2001; 103: 90–97.
9. Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel ML. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci USA 1996; 93: 12496–12501.
10. Chow YH, Chiang BL, Lee YL, Chi WK, Lin WC, Chen YT, et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998; 160: 1320–1329.
11. Moingeon P. Cancer vaccines. Vaccine 2001; 19: 1305–1326.
12. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998; 338: 1405–1412.
13. King Jr. JC, Lagos R, Bernstein DI, Piedra PA, Kotloff K, Bryant M, et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis 1998; 177: 1394–1397.
14. Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999; 282: 137–144.
15. Coon B, An LL, Whitton JL, von Herrath MG. DNA immunization to prevent autoimmune diabetes. J Clin Invest 1999; 104: 189–194.
16. Von Herrath MG, Whitton JL. DNA vaccination to treat autoimmune diabetes. Ann Med 2000; 32: 285–292.
17. McHugh RS, Nagarajan S, Wang YC, Sell KW, Selvaraj P. Protein transfer of glycosyl-phosphatidylinositol-B7–1 into tumor cell membranes: a novel approach to tumor immunotherapy. Cancer Res 1999; 59: 2433–2437.
18. Poloso NJ, Nagarajan S, Bumgarner GW, Selvaraj P. Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunostimulatory molecules. Vaccine 2001; 19: 2029–2038.
19. Tartaglia J, Bonnet M, Berinstein N, Barber B, Klein M, Moingeon P. Therapeutic vaccines against melanoma and colorectal cancer. Vaccine 2001; 19: 2571–2575.
20. Kochenderfer JN, Molldrem JJ. Leukemia vaccines. Curr Oncol Rep 2001; 3: 193–200.
21. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001; 107: 477–484.
22. Chen Y, Emtage P, Zhu Q, Foley R, Muller W, Hitt M, et al. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther 2001; 8: 316–323.
23. Sivanandham M, Shaw P, Bernik SF, Paoletti E, Wallack MK. Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice. Cancer Immunol Immunother 1998; 46: 261–267.
24. Simone EA, Wegmann DR, Eisenbarth GS. Immunologic “vaccination” for the prevention of autoimmune diabetes (type 1A). Diabetes Care 1999; 22: 7–15.
25. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979–982.
26. Naz RK, Zhu X, Kadam AL. Cloning and sequencing of cDNA encoding for a novel human testis-specific contraceptive vaccinogen: role in immunocontraception. Mol Reprod Dev 2001; 60: 116–127.
27. Santhanam R, Naz RK. Novel human testis-specific cDNA: molecular cloning, expression and immunobiological effects of the recombinant protein. Mol Reprod Dev 2001; 60: 1–12.
28. Hasegawa A, Hamada Y, Shigeta M, Koyama K. Contraceptive potential of synthetic peptides of zona pellucida protein (ZPA). J Reprod Immunol 2002; 53: 91–98.
29. Lillibridge SR, Bell AJ, Roman RS. Centers for disease control and prevention bioterrorism preparedness and response. Am J Infect Control 1999; 27: 463–464.
30. Cieslak TJ, Christopher GW, Kortepeter MG, Rowe JR, Pavlin JA, Culpepper RC, et al. Immunization against potential biological warfare agents. Clin Infect Dis 2000; 30: 843–850.
31. Scharton-Kersten T, Glenn GM, Vassell R, Yu J, Walwender D, Alving CR. Principles of transcutaneous immunization using cholera toxin as an adjuvant. Vaccine 1999; 17: S37–S43.
32. Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR, Alving CR. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun 1999; 67: 1100–1106.
33. Langridge WH. Edible vaccines. Sci Am 2000; 283: 66–71.
34. Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med 1998; 4: 607–609.
35. Zhao Z, Leong KW. Controlled delivery of antigens and adjuvants in vaccine development. J Pharm Sci 1996; 85: 1261–1270.
36. Gupta RK, Chang AC, Siber GR. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems. Dev Biol Stand 1998; 92: 63–78.
37. Poland GA, Jacobson RM. Vaccine safety: injecting a dose of common sense. Mayo Clin Proc 2000; 75: 135–139.
38. Poland GA, Jacobson RM. Understanding those who do not understand: a brief review of the anti-vaccine movement. Vaccine 2001; 19: 2440–2445.